Abstract
Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have